Summary
Eight healthy male volunteers took a single oral dose of one of the following: Rythmodan (conventionally formulated disopyramide) 150 mg; Rythmodan 250 mg; Rythmodan Retard (controlled-release disopyramide) 250 mg; placebo. The subjects were allocated double-blind to sessions and treatments according to a Latin square design.
In each session pupil diameter, heart rate, salivation, and QT interval were measured immediately before and at 1, 2, 3, 4, 6, 8, and 24 h after the drug. QT interval was corrected for heart rate (QT60). Plasma concentrations of total and unbound disopyramide were also determined at each time point.
Both formulations of disopyramide reduced salivary output and increased QT60 interval, but there was no significant difference between the effects of the three active treatments. Neither formulation had any effect on pupil diameter or heart rate.
The peak plasma concentration of unbound disopyramide was reached 2 h after Rythmodan and 4 h after Rythmodan Retard. The peak plasma concentration of disopyramide was significantly lower after Rythmodan Retard 250 mg than after Rythmodan 250 mg.
The plasma concentration of unbound disopyramide was positively correlated with the reduction in salivation and prolongation of the QT60 interval. The reduction in salivation is likely to reflect blockade of muscarinic receptors by disopyramide, whereas the increase in QT60 interval is likely to be related to a direct effect of the drug on the heart.
The results of this single-dose study do not indicate that disopyramide in the controlled-release formulation would be better tolerated by patients than conventionally formulated disopyramide.
This is a preview of subscription content, log in via an institution to check access.
References
Ahmad S, Sheikh AI, Meeran MK (1979) Disopyramide-induced acute psychosis. Chest 76: 712
Aitio M-L, Allonen H, Kanto J, Mantyla R (1982) The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans. Int J Clin Pharmacol Ther Toxicol 20: 219–226
Baines MW, Davies JE, Kellett DN, Munt PL (1976) Some pharmacologic effects of disopyramide and a metabolite. J Int Med Res 4 [Suppl 1]: 5–7
Birkhead JS, Vaughan Williams EM (1977) Dual effects of disopyramide on atrial and atrioventricular conduction and refractory periods. Br Heart J 39: 657–660
Boland J, Lisin N, Marcelle R, Carlier J (1976) Effets du disopyramide intraveineux sur l'hémodynamique de patients hospitalisés en unités de soins intensifs. Arch Int Pharmacodyn Ther 224: 145–151
Brion N, Beaumont D, Advenier C (1988) Evaluation of the anti-muscarinic activity of atropine, terfenadine and mequitazine in healthy volunteers. Br J Clin Pharmacol 25: 27–32
Brogden RN, Todd PA (1987) Disopyramide — A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias. Drugs 34: 151–187
Brown BS, Gorczynski RJ, Reynolds RD, Shaffer JE (1986) Comparison of the parasympatholytic activity of ACC-9358 and disopyramide. Br J Pharmacol 87: 89–95
Bryson SM, Whiting B, Lawrence JR (1978) Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability. Br J Clin Pharmacol 6: 409–419
Echizen H, Saima S, Umeda N, Ishizaki T (1986) Protein binding of disopyramide in liver cirrhosis and nephrotic syndrome. Clin Pharmacol Ther 40: 274–280
Frucht J, Freimann I, Merin S (1984) Ocular side effects of disopyramide. Br J Ophthalmol 68: 890–891
Galeazzi RL, Benet LZ, Sheiner LB (1976) Relationship between the pharmacokinetics and pharmacodynamics of procainamide. Clin Pharmacol Ther 20: 278–289
Giacomini KM, Blaschke T (1984) Effect of concentration-dependent binding to plasma proteins on the pharmacokinetics and pharmacodynamics of disopyramide. Clin Pharmacokin 9 [Suppl 1]: 42–48
Heel RC, Brogden RN, Speight TM, Avery GS (1978) Disopyramide: A review of its pharmacological properties and therapeutic use in treating cardiac arrhythmias. Drugs 15: 331–368
Hinderling PH, Garrett ER (1976a) Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans. J Pharmacokin Biopharm 4: 199–230
Hinderling PH, Garrett ER (1976b) Pharmacodynamics of the antiarrhythmic disopyramide in healthy humans: correlation of the kinetics of the drug and its effects. J Pharmacokin Biopharm 4: 231–242
Iisalo E, Aaltonen L (1984) Anticholinergic activity in the serum of patients receiving maintenance disopyramide therapy. Br J Clin Pharmacol 17: 325–329
Ilett KF, Tjokrosetio RR, Benzie JL (1983) Correlation of disopyramide and N-desalkyl disopyramide plasma levels and anticholinergic side-effects. Aust J Hosp Pharm 13: 142–145
Jensen G, Sigurd B, Uhrenholt A (1976) Circulatory effects of intravenous disopyramide in heart failure. J Int Med Res 4 [Suppl 1]: 42–45
Longmore J, Berry JL, Szabadi E, Bradshaw CM (1990) Comparison of two formulations of disopyramide on cholinergic functions in human volunteers. Br J Clin Pharmacol 29: 633P
Karim A, Nissen C, Azarnoff DL (1982) Clinical pharmacokinetics of disopyramide. J Pharmacokin Biopharm 10: 465–494
Marrott PK, Ruttley MST, Winterbottam JT, Muir JR (1976) A study of the acute electrophysiological and cardiovascular action of disopyramide in man. Eur J Cardiol 4: 303–312
McNemar Q (1969) Psychological statistics, 4 ed. Wiley, New York
Mirro MJ, Manalan AS, Baily JC, Watanabe AM (1980) Anticholinergic effects of disopyramide and quinidine on guinea pig myocardium: mediation by direct muscarinic receptor blockade. Circulation Res 47: 855–865
Nauta ILD, van de Calseyde JF (1981) Study of an anti-arrhythmic agent, disopyramide, in delayed action form (“Ritmoforine” Retard). Curr Med Res Opinion 7: 215–226
Niarchos AP (1976) Disopyramide serum level and arrhythmia conversion. Am Heart J 37: 861–867
Peck RE (1959) The SHP test: an aid in the detection and measurement of depression. Arch Gen Psych 1: 35–40
Raghow G, Meyer HC, Straughn AB (1985) Determination of free disopyramide concentrations using ultrafiltration and Enzyme Multiplied Immunoassay. Ther Drug Mon 7: 466–471
Sneddon JM, Turner P (1969) The interaction of local guanethidine and sympathomimetic amines in the human eye. Arch Ophthalmol 81: 622–627
Spurrell RAJ, Thorburn CW, Camm J, Sowton E, Deuchar DC (1975) Effects of disopyramide on electrophysiological properties of the specialised conduction system in man and on accessory atrioventricular pathway in the Wolff-Parkinson-White syndrome. Br Heart J 37: 861–867
Szabadi E, Bradshaw CM (1986) Antidepressant drugs and the autonomic nervous system. In: Deakin JFW (ed) The biology of depression. Royal College of Psychiatrists/Gaskell. London, pp 190–220
Szabadi E, Gaszner P, Bradshaw CM (1980) The peripheral anticholinergic activity of tricyclic antidepressants: comparison of amitriptyline and desipramine. Br J Psychiatry 137: 617–624
Whiting B, Holford NHG, Sheiner LB (1980) Quantitative analysis of the disopyramide concentration-effect relationship. Br J Clin Pharmacol 9: 67–75
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Longmore, J., Berry, J.L., Szabadi, E. et al. A comparison of the anticholinergic effects of two formulations of disopyramide in healthy volunteers. Eur J Clin Pharmacol 39, 305–309 (1990). https://doi.org/10.1007/BF00315118
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315118